Galper BZ, et al. - In patients with stable coronary disease, researchers assessed the cost-effectiveness of newer drug-eluting stent (DES) that may permit for shorter dual antiplatelet therapy (DAPT) duration. They compared treatment with newer DES platforms followed by 1 or 3 months of DAPT vs standard second-generation DES followed by 6 or 12 months of DAPT. They used a Markov model that simulated distinct health states over a lifetime. Findings suggested that in patients at elevated risk of bleeding, it is likely to be cost-effective to use a DES that allows 3 months of DAPT without increasing stent-related events. However, such cost-effectiveness was not seen among those with average bleeding risk.